NASDAQ:KERN Akerna (KERN) Stock Forecast, Price & News $0.17 -0.01 (-5.44%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$0.17▼$0.2050-Day Range$0.18▼$0.6152-Week Range$0.17▼$2.80Volume438,944 shsAverage Volume334,937 shsMarket Capitalization$1.36 millionP/E RatioN/ADividend YieldN/APrice Target$1.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Akerna MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside475.4% Upside$1.00 Price TargetShort InterestHealthy1.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.56 out of 5 stars 3.0 Analyst's Opinion Consensus RatingAkerna has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.00, Akerna has a forecasted upside of 475.4% from its current price of $0.17.Amount of Analyst CoverageAkerna has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.85% of the float of Akerna has been sold short.Short Interest Ratio / Days to CoverAkerna has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akerna has recently increased by 1,032.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkerna does not currently pay a dividend.Dividend GrowthAkerna does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KERN. Previous Next 2.0 News and Social Media Coverage News SentimentAkerna has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Akerna this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for KERN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Akerna to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akerna insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.15% of the stock of Akerna is held by insiders.Percentage Held by InstitutionsOnly 21.97% of the stock of Akerna is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Akerna is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akerna is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Akerna (NASDAQ:KERN) StockAkerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.Read More KERN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KERN Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comCritical Review: Akerna (NASDAQ:KERN) versus Cosmos Group (OTCMKTS:COSG)September 20, 2023 | americanbankingnews.comAkerna (NASDAQ:KERN) vs. SBI (OTCMKTS:SBHGF) Financial SurveySeptember 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 19, 2023 | americanbankingnews.comAkerna (NASDAQ:KERN) Stock Price Up 7.1%September 11, 2023 | benzinga.comGryphon Digital Mining to Provide Updates at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 11, 2023 | benzinga.comWhy Akerna Stock Is Exploding Higher TodaySeptember 8, 2023 | finance.yahoo.comGryphon Digital Mining to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 24, 2023 | bizjournals.comFrom coffee shop to pot shop: Change is afoot at original Uptown EspressoSeptember 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 11, 2023 | bizjournals.comPOSaBIT promotes IBM vet Chris Baker to chief operations officerAugust 3, 2023 | msn.comZimVie Inc. (ZIMV) Tops Q2 Earnings and Revenue EstimatesJuly 31, 2023 | fool.comAkerna (NASDAQ: KERN)June 6, 2023 | finance.yahoo.comAll You Need to Know About Akerna Corp. (KERN) Rating Upgrade to BuyJune 3, 2023 | msn.comHC Wainwright & Co. Reiterates Akerna (KERN) Neutral RecommendationMay 17, 2023 | finance.yahoo.comAkerna First Quarter 2023 Earnings: US$0.48 loss per share (vs US$13.89 loss in 1Q 2022)May 1, 2023 | finanznachrichten.deAkerna Corp.: Akerna Announces Sale of Software Business to MJ Freeway Acquisition Co, Coinciding with Merger with Gryphon Digital MiningApril 29, 2023 | marketwatch.comAkerna to Sell its Cannabis Software BusinessApril 29, 2023 | msn.comAkerna divests its cannabis software business to SPAC MJ FreewayApril 28, 2023 | finance.yahoo.comAkerna Announces Sale of Software Business to MJ Freeway Acquisition Co, Coinciding with Merger with Gryphon Digital MiningApril 26, 2023 | finance.yahoo.comGryphon Digital Mining to Present at the Ladenburg Thalmann Tech Expo 2023April 7, 2023 | finance.yahoo.comAkerna Receives Superior Acquisition Proposal, Terminates Agreement with POSaBITMarch 21, 2023 | finance.yahoo.comAkerna Announces Financial Results for Fourth Quarter and Full Year 2022February 15, 2023 | finance.yahoo.comAkerna Provides Update on Recently Announced TransactionsFebruary 1, 2023 | finance.yahoo.comAkerna Regains Compliance with NASDAQ Continued Listing RequirementsJanuary 12, 2023 | benzinga.comWhy Akerna Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving PremarketNovember 29, 2022 | finance.yahoo.comPass the Pre-Rolls, Please: Thanksgiving Holiday Cannabis Sales See Double-Digit Year-Over-Year GrowthNovember 14, 2022 | finance.yahoo.comAkerna Corp. (KERN) Reports Q3 Loss, Misses Revenue EstimatesSee More Headlines Receive KERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akerna and its competitors with MarketBeat's FREE daily newsletter. Email Address KERN Company Calendar Last Earnings8/14/2023Today9/27/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Nondepository credit institutions Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KERN CUSIPN/A CIK1755953 Webwww.akerna.com Phone888-932-6537FaxN/AEmployees112Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.00 High Stock Price Forecast$1.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+428.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($7.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,060,000.00 Net Margins-251.68% Pretax Margin-175.32% Return on Equity-475.50% Return on Assets-71.74% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.20 Sales & Book Value Annual Sales$13.65 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value($1.52) per share Price / Book-0.12Miscellaneous Outstanding Shares7,800,000Free Float7,556,000Market Cap$1.48 million OptionableNot Optionable Beta2.67 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Jessica Billingsley (Age 45)Founder, CEO & Chairman Comp: $304.5kMr. Larry Dean Ditto Jr. (Age 56)Chief Financial Officer Comp: $159.47kMr. David R. McCullough (Age 46)Chief Technology Officer Comp: $240.43kGeorgia JablonCommunications Mang.Key CompetitorsChina SXT PharmaceuticalsNASDAQ:SXTCTransCode TherapeuticsNASDAQ:RNAZRubius TherapeuticsNASDAQ:RUBYChina PharmaNYSE:CPHIAssureNASDAQ:IONMView All Competitors KERN Stock - Frequently Asked Questions Should I buy or sell Akerna stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akerna in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KERN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KERN, but not buy additional shares or sell existing shares. View KERN analyst ratings or view top-rated stocks. What is Akerna's stock price forecast for 2023? 1 analysts have issued 12 month target prices for Akerna's stock. Their KERN share price forecasts range from $1.00 to $1.00. On average, they expect the company's share price to reach $1.00 in the next year. This suggests a possible upside of 428.5% from the stock's current price. View analysts price targets for KERN or view top-rated stocks among Wall Street analysts. How have KERN shares performed in 2023? Akerna's stock was trading at $0.6902 at the start of the year. Since then, KERN shares have decreased by 72.6% and is now trading at $0.1892. View the best growth stocks for 2023 here. Are investors shorting Akerna? Akerna saw a increase in short interest in September. As of September 15th, there was short interest totaling 123,400 shares, an increase of 1,032.1% from the August 31st total of 10,900 shares. Based on an average trading volume of 315,800 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.9% of the company's stock are sold short. View Akerna's Short Interest. When is Akerna's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our KERN earnings forecast. How were Akerna's earnings last quarter? Akerna Corp. (NASDAQ:KERN) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.20. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.66 million. Akerna had a negative trailing twelve-month return on equity of 475.50% and a negative net margin of 251.68%. What ETF holds Akerna's stock ? Amplify Seymour Cannabis ETF holds 13,319 shares of KERN stock, representing 0.03% of its portfolio. What other stocks do shareholders of Akerna own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akerna investors own include KushCo (KSHB), Organigram (OGI), Supreme Cannabis (SPRWF), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Medical Marijuana (MJNA), MariMed (MRMD), Matinas BioPharma (MTNB), CNBX Pharmaceuticals (CNBX) and DHT (DHT). What is Akerna's stock symbol? Akerna trades on the NASDAQ under the ticker symbol "KERN." How do I buy shares of Akerna? Shares of KERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akerna's stock price today? One share of KERN stock can currently be purchased for approximately $0.19. How much money does Akerna make? Akerna (NASDAQ:KERN) has a market capitalization of $1.48 million and generates $13.65 million in revenue each year. The company earns $-79,060,000.00 in net income (profit) each year or ($7.37) on an earnings per share basis. How many employees does Akerna have? The company employs 112 workers across the globe. How can I contact Akerna? Akerna's mailing address is 1601 ARAPAHOE STREET, DENVER CO, 80202. The official website for the company is www.akerna.com. The company can be reached via phone at 888-932-6537 or via email at ir@akerna.com. This page (NASDAQ:KERN) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akerna Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.